<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652169</url>
  </required_header>
  <id_info>
    <org_study_id>PRF-TAT</org_study_id>
    <nct_id>NCT02652169</nct_id>
  </id_info>
  <brief_title>PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4</brief_title>
  <acronym>PRF-TAT</acronym>
  <official_title>Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet rich fibrin (PRF) is a new therapy option for chronic wounds with yet unproven&#xD;
      therapeutic efficacy. This randomised controlled trial aims to provide evidence of the&#xD;
      efficacy of PRF as monotherapy as well as a growth promoting carrier matrix for antimicrobial&#xD;
      compounds. The investigators therefore designed a four armed trial with three PRF arms which&#xD;
      are compared to each other as well as to an active comparator. The treatment arms are as&#xD;
      follows:&#xD;
&#xD;
      Study arm 1: PRF with amikacin and teicoplanin Study arm 2: PRF with placebo (0.9% sodium&#xD;
      chloride) Study arm 3: PRF with PHMB (polyhexanid) plus Macrogolol (Lavasorb®) Study arm 4:&#xD;
      Acticoat 7® wound dressing as active control Patients with infected chronic wounds may be&#xD;
      included in this trial. Infection shall be diagnosed by an experienced senior infectious&#xD;
      diseases specialist. Patients with untreated peripheral vascular occlusive disease as defined&#xD;
      by an ABI (ancle brachial index) of &lt; 0,7 are excluded from the trial as are patients with an&#xD;
      uncontrolled diabetes mellitus or patients who have not received sufficient treatment for a&#xD;
      diabetic foot syndrome. Any underlying illness will be treated following standard of care. In&#xD;
      case of chronic venous insufficiency four-layered compression bandages will be applied each&#xD;
      visit if tolerated by the patient. Alternatively compression stockings (Class III) are&#xD;
      permitted. This is mentioned as &quot;Disease specific treatment&quot; in the protocol.&#xD;
&#xD;
      Patients will receive treatment for 56 days. After 28 and 56 days the wound surface will be&#xD;
      compared to the baseline. Infection parameters (c-reactive protein and leucocyte count) will&#xD;
      be measured weekly. Evaluation of systemic antimicrobial therapy will be performed at each&#xD;
      visit. Systemic antimicrobial therapy is started at the discretion of a senior infectious&#xD;
      diseases specialist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in wound area</measure>
    <time_frame>day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in necessity to initiate systemic antimicrobial therapy based on the opinion of a senior infectious disease consultant arises (subjective assessment based on wound inflammation, serum c-reactive protein levels and leucocyte count)</measure>
    <time_frame>day 0, 7, 14, 21, 28, 35, 42, 49, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevation of C-reactive protein over 7 mg/dl (normal value 0.5 mg/dl)</measure>
    <time_frame>day 0, 7, 14, 21, 28, 35, 42, 49, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to sterility of the wound</measure>
    <time_frame>day 0, 7, 14, 21, 28, 35, 42, 49, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative wound volume and wound area reduction</measure>
    <time_frame>on day 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug resistant bacteria in the wound</measure>
    <time_frame>day 0, 7, 14, 21, 28, 35, 42, 49, 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug resistant bacteria in a swab of the tissue surrounding the wound or a Z-swab of the torso</measure>
    <time_frame>on day 28 and 56</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Skin Ulcer</condition>
  <arm_group>
    <arm_group_label>Study arm 1 - PRF plus amikacin and teicoplanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm 2 - PRF plus normal saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRF mixed with normal saline is sprayed on the patients' ulcer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm 3 - PRF mixed with PHMB plus Macrogolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm 4 - Acticoat 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A silver gauze (Acticoat 7®) is applied to the patients' ulcer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRF mixed with amikacin and teicoplanin</intervention_name>
    <description>PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer</description>
    <arm_group_label>Study arm 1 - PRF plus amikacin and teicoplanin</arm_group_label>
    <other_name>PRF plus amikacin/teicoplanin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRF mixed with PHMB plus Macrogolol</intervention_name>
    <description>PRF, mixed with Lavasorb is applied to the chronic ulcer</description>
    <arm_group_label>Study arm 3 - PRF mixed with PHMB plus Macrogolol</arm_group_label>
    <other_name>PRF plus Lavasorb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRF plus normal saline</intervention_name>
    <description>PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer</description>
    <arm_group_label>Study arm 2 - PRF plus normal saline</arm_group_label>
    <other_name>PRF plus sodium chloride 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Silver gauze</intervention_name>
    <description>Acticoat 7 silver wound dressing is applied to the chronic ulcer</description>
    <arm_group_label>Study arm 4 - Acticoat 7</arm_group_label>
    <other_name>Acticoat 7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged over 18 who are able to give informed consent&#xD;
&#xD;
          -  Chronic venous ulcer with localized non-systemic soft-tissue infection diagnosed by&#xD;
             senior infectious diseases specialist based on US FDA Guidance for Industry Chronic&#xD;
             cutaneous ulcer and burn wounds June 2006:&#xD;
&#xD;
               -  slough and necrotic tissue&#xD;
&#xD;
               -  exsudate&#xD;
&#xD;
               -  smell&#xD;
&#xD;
               -  inflammation&#xD;
&#xD;
               -  presence of granulation tissue&#xD;
&#xD;
               -  pain&#xD;
&#xD;
          -  Wound size ≥ 5 cm2 and &lt; 200 cm2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-treated diabetes mellitus, HbA1c &gt; 12 mg/dl&#xD;
&#xD;
          -  Non treated (orthopaedic shoe) diabetic foot syndrome&#xD;
&#xD;
          -  ABI &lt; 0,7&#xD;
&#xD;
          -  Wound size 15 cm2 and &gt; 200 cm2&#xD;
&#xD;
          -  CRP &gt; 5 mg/dl&#xD;
&#xD;
          -  Leucocytes &gt; 15.000 /μl&#xD;
&#xD;
          -  Infection of another site&#xD;
&#xD;
          -  Infection of the ulcer with a pathogen with inherent resistance to amikacin and&#xD;
             teicoplanin&#xD;
&#xD;
          -  Known osteomyelitis&#xD;
&#xD;
          -  Known erysipelas&#xD;
&#xD;
          -  Known phlegmon&#xD;
&#xD;
          -  Complicated deep tissue infection not solely treatable with PRF plus antimicrobial&#xD;
             therapy in the opinion of a senior infectious diseases specialist&#xD;
&#xD;
          -  Planned systemic antimicrobial therapy&#xD;
&#xD;
          -  Active viral hepatitis (A/B/C) or active HIV infection or active syphilis&#xD;
&#xD;
          -  Increased sensitivity to amikacin or teicoplanin, PHMB or macrogolol&#xD;
&#xD;
          -  Increased sensitivity to tramexanic acid or batroxobin&#xD;
&#xD;
          -  Presence of neoplastic growth in the ulcer&#xD;
&#xD;
          -  Thrombocytopenic patients (&lt;150.000 G/L)&#xD;
&#xD;
          -  Haemoglobin &lt; 95 g/L&#xD;
&#xD;
          -  Known pregnancy or lactation&#xD;
&#xD;
          -  Severe renal impairment (creatinine clearance &lt;30 ml/min)&#xD;
&#xD;
          -  History or clinical signs of impairment of the cochlea or vestibularis system&#xD;
&#xD;
          -  Neuromuscular diseases (i.e. Myasthenia gravis, Parkinson's disease)&#xD;
&#xD;
          -  Aminoglycoside treatment less than four weeks before inclusion&#xD;
&#xD;
          -  Other reasons opposing the study participation on the discretion of the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Thalhammer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian Thalhammer, Prof. Dr.</last_name>
    <phone>0043140400</phone>
    <phone_ext>44400</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>4440</phone_ext>
      <email>florian.thalhammer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela A Knafl, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias G Vossen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Florian Thalhammer</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr.med.univ.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

